4.7 Article

Initiating Intramuscular Depot Medroxyprogesterone Acetate (DMPA-IM) Increases Frequencies of Th17-like Human Immunodeficiency Virus (HIV) Target Cells in the Genital Tract of Women in South Africa: A Randomized Trial

Journal

CLINICAL INFECTIOUS DISEASES
Volume 75, Issue 11, Pages 2000-2011

Publisher

OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciac284

Keywords

hormonal contraception; HIV risk; Th17 cells; mucosal barrier integrity

Funding

  1. Bill & Melinda Gates Foundation
  2. US Agency for International Development
  3. President's Emergency Plan for AIDS Relief
  4. Swedish International Development Cooperation Agency (SIDA)
  5. UN Population Fund
  6. US National Institute of Child Health and Human Development
  7. ECHO Biological Mechanisms Ancillary Study
  8. National Institutes of Health [NIH F32HD102290, R01HD089831-05]
  9. South African Medical Research Council

Ask authors/readers for more resources

In the ECHO trial, we found that the use of intramuscular depot medroxyprogesterone acetate (DMPA-IM) was associated with a significant increase in HIV-susceptible Th17-like cells, while the copper-IUD or levonorgestrel implant had no such effect. Proteomic analyses suggest that this increase in Th17-like cells driven by DMPA might be counteracted by their role in maintaining mucosal barrier integrity.
Background Cervicovaginal CD4+ T cells are preferential targets for human immunodeficiency virus (HIV) infection and have consequently been used as a proxy measure for HIV susceptibility. The ECHO randomized trial offered a unique opportunity to consider the association between contraceptives and Th17-like cells within a trial designed to evaluate HIV risk. In a mucosal substudy of the ECHO trial, we compared the impact of initiating intramuscular depot medroxyprogesterone acetate (DMPA-IM), copper-IUD, and the levonorgestrel (LNG) implant on cervical T cells. Methods Cervical cytobrushes from 58 women enrolled in the ECHO trial were collected at baseline and 1 month after contraceptive initiation. We phenotyped cervical T cells using multiparameter flow cytometry, characterized the vaginal microbiome using 16s sequencing, and determined proteomic signatures associated with Th17-like cells using mass spectrometry. Results Unlike the LNG implant or copper-IUD, DMPA-IM was associated with higher frequencies of cervical Th17-like cells within 1 month of initiation (P = .012), including a highly susceptible, activated population co-expressing CD38, CCR5, and alpha 4 beta 7 (P = .003). After 1 month, women using DMPA-IM also had more Th17-like cells than women using the Cu-IUD (P = .0002) or LNG implant (P = .04). Importantly, in women using DMPA-IM, proteomic signatures signifying enhanced mucosal barrier function were associated with the increased abundance of Th17-like cells. We also found that a non-Lactobacillus-dominant microbiome at baseline was associated with more Th17-like cells post-DMPA-IM (P = .03), although this did not influence barrier function. Conclusions Our data suggest that DMPA-IM-driven accumulation of HIV-susceptible Th17-like cells might be counteracted by their role in maintaining mucosal barrier integrity. Cervicovaginal Th17-like cells significantly increased in women after initiation of intramuscular depot medroxyprogesterone acetate (DMPA-IM) but not the copper-IUD or the levonorgestrel implant. Proteomic analyses suggest that this DMPA-driven accumulation of HIV-susceptible Th17-like cells might be counteracted by their role in maintaining mucosal barrier integrity.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available